Vaccines Market (Vaccine: Inactivated, Live Attenuated, Toxoid, Conjugate, and Others; and Valance: Monovalent and Multivalent) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Vaccines Market (Vaccine: Inactivated, Live Attenuated, Toxoid, Conjugate, and Others; and Valance: Monovalent and Multivalent) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Vaccines Market – Scope of Report

TMR’s report on the global vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vaccines market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vaccines market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the vaccines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vaccines market.

The report delves into the competitive landscape of the global vaccines market. Key players operating in the global vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vaccines market profiled in this report.

Key Questions Answered in Global vaccines Market Report
  • What is the sales/revenue generated by vaccines across all regions during the forecast period?
  • What are the opportunities in the global vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Vaccines Market – Research Objectives and Research Approach

The comprehensive report on the global vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vaccines market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vaccines Market
4. Market Overview
4.1. Introduction
4.2. Definition
4.3. Industry Evolution / Developments
4.4. Overview
4.5. Market Dynamics
  4.5.1. Drivers
  4.5.2. Restraints
  4.5.3. Opportunities
4.6. Global Vaccines Market Analysis and Forecast, 2017-2031
  4.6.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario
5.2. Key Distribution Strategies
5.3. Pricing Analysis
5.4. Patents on Vaccines
5.5. Technological Advancements in Vaccines
5.6. Vaccine Type - Overview
5.7. COVID-19 Pandemic Impact on Industry
6. Global Vaccines Market Analysis and Forecast, by Vaccine
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine, 2017-2031
  6.3.1. Inactivated
  6.3.2. Live Attenuated
  6.3.3. Toxoid
  6.3.4. Conjugate
  6.3.5. Others
6.4. Market Attractiveness Analysis, by Vaccine
7. Global Vaccines Market Analysis and Forecast, by Valance
7.1. Introduction & Definition
7.2. Developments
7.3. Market Value Forecast, by Valance, 2017-2031
  7.3.1. Monovalent
  7.3.2. Multivalent
7.4. Market Attractiveness Analysis, by Valance
8. Global Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
  8.3.1. Oral
  8.3.2. Injectable
  8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Vaccines Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Indication, 2017-2031
  9.3.1. Influenza
  9.3.2. Hepatitis
  9.3.3. Polio
  9.3.4. Meningococcal Disease
  9.3.5. Pneumococcal Disease
  9.3.6. DTP
  9.3.7. Rotavirus
  9.3.8. MMR
  9.3.9. Human Papilloma Virus
  9.3.10. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Vaccines Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
  10.3.1. Institutional Sales
  10.3.2. Hospital Pharmacies
  10.3.3. Retail Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Vaccines Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017-2031
  11.2.1. North America
  11.2.2. Europe
  11.2.3. Asia Pacific
  11.2.4. Latin America
  11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Vaccines Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Vaccine, 2017-2031
  12.3.1. Inactivated
  12.3.2. Live Attenuated
  12.3.3. Toxoid
  12.3.4. Conjugate
  12.3.5. Others
12.4. Market Value Forecast, by Valance, 2017-2031
  12.4.1. Monovalent
  12.4.2. Multivalent
12.5. Market Value Forecast, by Route of Administration, 2017-2031
  12.5.1. Oral
  12.5.2. Injectable
  12.5.3. Others
12.6. Market Value Forecast, by Indication, 2017-2031
  12.6.1. Influenza
  12.6.2. Hepatitis
  12.6.3. Polio
  12.6.4. Meningococcal Disease
  12.6.5. Pneumococcal Disease
  12.6.6. DTP
  12.6.7. Rotavirus
  12.6.8. MMR
  12.6.9. Human Papilloma Virus
  12.6.10. Others
12.7. Market Value Forecast, by Distribution Channel, 2017-2031
  12.7.1. Institutional Sales
  12.7.2. Hospital Pharmacies
  12.7.3. Retail Pharmacies
12.8. Market Value Forecast, by Country/sub-region, 2017-2031
  12.8.1. U.S.
  12.8.2. Canada
12.9. Market Attractiveness Analysis
  12.9.1. By Vaccine
  12.9.2. By Valance
  12.9.3. By Route of Administration
  12.9.4. By Indication
  12.9.5. By Distribution Channel
  12.9.6. By Country
13. Europe Vaccines Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Vaccine, 2017-2031
  13.3.1. Inactivated
  13.3.2. Live Attenuated
  13.3.3. Toxoid
  13.3.4. Conjugate
  13.3.5. Others
13.4. Market Value Forecast, by Valance, 2017-2031
  13.4.1. Monovalent
  13.4.2. Multivalent
13.5. Market Value Forecast, by Route of Administration, 2017-2031
  13.5.1. Oral
  13.5.2. Injectable
  13.5.3. Others
13.6. Market Value Forecast, by Indication, 2017-2031
  13.6.1. Influenza
  13.6.2. Hepatitis
  13.6.3. Polio
  13.6.4. Meningococcal Disease
  13.6.5. Pneumococcal Disease
  13.6.6. DTP
  13.6.7. Rotavirus
  13.6.8. MMR
  13.6.9. Human Papilloma Virus
  13.6.10. Others
13.7. Market Value Forecast, by Distribution Channel, 2017-2031
  13.7.1. Institutional Sales
  13.7.2. Hospital Pharmacies
  13.7.3. Retail Pharmacies
13.8. Market Value Forecast, by Country/sub-region, 2017-2031
  13.8.1. Germany
  13.8.2. U.K.
  13.8.3. France
  13.8.4. Italy
  13.8.5. Spain
  13.8.6. Rest of Europe
13.9. Market Attractiveness Analysis
  13.9.1. By Vaccine
  13.9.2. By Valance
  13.9.3. By Route of Administration
  13.9.4. By Indication
  13.9.5. By Distribution Channel
  13.9.6. By Country/Sub-region
14. Asia Pacific Vaccines Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Vaccine, 2017-2031
  14.3.1. Inactivated
  14.3.2. Live Attenuated
  14.3.3. Toxoid
  14.3.4. Conjugate
  14.3.5. Others
14.4. Market Value Forecast, by Valance, 2017-2031
  14.4.1. Monovalent
  14.4.2. Multivalent
14.5. Market Value Forecast, by Route of Administration, 2017-2031
  14.5.1. Oral
  14.5.2. Injectable
  14.5.3. Others
14.6. Market Value Forecast, by Indication, 2017-2031
  14.6.1. Influenza
  14.6.2. Hepatitis
  14.6.3. Polio
  14.6.4. Meningococcal Disease
  14.6.5. Pneumococcal Disease
  14.6.6. DTP
  14.6.7. Rotavirus
  14.6.8. MMR
  14.6.9. Human Papilloma Virus
  14.6.10. Others
14.7. Market Value Forecast, by Distribution Channel, 2017-2031
  14.7.1. Institutional Sales
  14.7.2. Hospital Pharmacies
  14.7.3. Retail Pharmacies
14.8. Market Value Forecast, by Country/sub-region, 2017-2031
  14.8.1. China
  14.8.2. India
  14.8.3. Japan
  14.8.4. Australia & New Zealand
  14.8.5. Rest of Asia Pacific
14.9. Market Attractiveness Analysis
  14.9.1. By Vaccine
  14.9.2. By Valance
  14.9.3. By Route of Administration
  14.9.4. By Indication
  14.9.5. By Distribution Channel
  14.9.6. By Country/Sub-region
15. Latin America Vaccines Market Analysis and Forecast
15.1. Introduction
15.2. Key Findings
15.3. Market Value Forecast, by Vaccine, 2017-2031
  15.3.1. Inactivated
  15.3.2. Live Attenuated
  15.3.3. Toxoid
  15.3.4. Conjugate
  15.3.5. Others
  15.3.6. Others
15.4. Market Value Forecast, by Valance, 2017-2031
  15.4.1. Monovalent
  15.4.2. Multivalent
15.5. Market Value Forecast, by Route of Administration, 2017-2031
  15.5.1. Oral
  15.5.2. Injectable
  15.5.3. Others
15.6. Market Value Forecast, by Indication, 2017-2031
  15.6.1. Influenza
  15.6.2. Hepatitis
  15.6.3. Polio
  15.6.4. Meningococcal Disease
  15.6.5. Pneumococcal Disease
  15.6.6. DTP
  15.6.7. Rotavirus
  15.6.8. MMR
  15.6.9. Human Papilloma Virus
  15.6.10. Others
15.7. Market Value Forecast, by Distribution Channel, 2017-2031
  15.7.1. Institutional Sales
  15.7.2. Hospital Pharmacies
  15.7.3. Retail Pharmacies
15.8. Market Value Forecast, by Country/sub-region, 2017-2031
  15.8.1. Brazil
  15.8.2. Mexico
  15.8.3. Rest of Latin America
15.9. Market Attractiveness Analysis
  15.9.1. By Vaccine
  15.9.2. By Valance
  15.9.3. By Route of Administration
  15.9.4. By Indication
  15.9.5. By Distribution Channel
  15.9.6. By Country/Sub-region
16. Middle East & Africa Vaccines Market Analysis and Forecast
16.1. Introduction
16.2. Key Findings
16.3. Market Value Forecast, by Vaccine, 2017-2031
  16.3.1. Inactivated
  16.3.2. Live Attenuated
  16.3.3. Toxoid
  16.3.4. Conjugate
  16.3.5. Others
16.4. Market Value Forecast, by Valance, 2017-2031
  16.4.1. Monovalent
  16.4.2. Multivalent
16.5. Market Value Forecast, by Route of Administration, 2017-2031
  16.5.1. Oral
  16.5.2. Injectable
  16.5.3. Others
16.6. Market Value Forecast, by Indication, 2017-2031
  16.6.1. Influenza
  16.6.2. Hepatitis
  16.6.3. Polio
  16.6.4. Meningococcal Disease
  16.6.5. Pneumococcal Disease
  16.6.6. DTP
  16.6.7. Rotavirus
  16.6.8. MMR
  16.6.9. Human Papilloma Virus
  16.6.10. Others
16.7. Market Value Forecast, by Distribution Channel, 2017-2031
  16.7.1. Institutional Sales
  16.7.2. Hospital Pharmacies
  16.7.3. Retail Pharmacies
16.8. Market Value Forecast, by Country/sub-region, 2017-2031
  16.8.1. GCC Countries
  16.8.2. South Africa
  16.8.3. Rest of Middle East & Africa
16.9. Market Attractiveness Analysis
  16.9.1. By Vaccine
  16.9.2. By Valance
  16.9.3. By Route of Administration
  16.9.4. By Indication
  16.9.5. By Distribution Channel
  16.9.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
  17.3.1. AstraZeneca
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
  17.3.2. GlaxoSmithKline PLC
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
  17.3.3. Sanofi Pasteur SA
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
  17.3.4. Pfizer Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
  17.3.5. Panacea Biotec
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
  17.3.6. Merck & Co., Inc.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
  17.3.7. Janssen Pharmaceutical Company
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
  17.3.8. Serus Institute of India Ltd
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
  17.3.9. Emergent BioSolutions Inc.
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
  17.3.10. CSL
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
  17.3.11. Bavarian Nordic
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
  17.3.12. IBSS BIOMED S.A.
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. Financial Overview
17.3.12.4. SWOT Analysis
17.3.12.5. Strategic Overview
  17.3.13. Novavax AB
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Product Portfolio
17.3.13.3. Financial Overview
17.3.13.4. SWOT Analysis
17.3.13.5. Strategic Overview
  17.3.14. Mitsubishi Tanabe Pharma Corporation
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Product Portfolio
17.3.14.3. Financial Overview
17.3.14.4. SWOT Analysis
17.3.14.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings